Fibrin Sealant in Esophageal Surgery
Not Applicable
Completed
- Conditions
- Anastomotic Leak
- Registration Number
- NCT03251040
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Brief Summary
Anastomotic leakage remains a major complication after esophageal surgery. Amongst other preventive measures, fibrin sealant is a promising adjunct to conventional anastomotic techniques. The investigators aimed to investigate feasibility of additional sealing by means of autologous fibrin sealant of the esophageal anastomosis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
- Aged 18 - 90 years
- Scheduled to undergo elective minimal invasive esophageal surgery with thoracic or cervical anastomosis (i.e. Ivor Lewis, Orringer or McKeown esophagectomy).
- physical status (American Society of Anesthesiologists) of 3 or lower
Exclusion Criteria
- Other malignancies
- Previous esophageal surgery were excluded
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Anastomotic leakage 30-day morbidity
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie fibrin sealant's role in preventing esophageal anastomotic leakage?
How does autologous activated fibrin sealant compare to standard-of-care techniques in esophageal surgery outcomes?
Are there specific biomarkers that predict successful sealing with autologous fibrin in esophageal anastomoses?
What adverse events are associated with autologous fibrin sealant use in esophageal surgery and how are they managed?
What combination therapies or alternative sealants are being explored for esophageal anastomosis in clinical trials?